Ravi K Goyal

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 31

Top Topics

Ejection Fraction

Brain Metastases

Top Venues

Breast cancer research and treatment

Future oncology (London, England)

Drugs - real world outcomes

This page only lists publications with an associated author ORCID identifier.

Publications

Muhammad Furqan, Siddharth Karanth, Ravi K Goyal, Beilei Cai, Julien Rombi, Keith L Davis, Nydia Caro, Teddy Saliba
Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future oncology (London, England) (2024)
Freny Vaghaiwalla Mody, Ravi K Goyal, Mayank Ajmera, Keith L Davis, Alpesh N Amin
Exploring the Association Between Heart Rate Control and Rehospitalization: A Real-World Analysis of Patients Hospitalized with Heart Failure with Reduced Ejection Fraction. Drugs - real world outcomes 11 (3) (2024)
Ravi K Goyal, Jingchuan Zhang, Keith L Davis, Martina Sluga-O'Callaghan, Peter A Kaufman
Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer. Breast cancer research and treatment (2024)
Muhammad Furqan, Siddharth Karanth, Ravi K Goyal, Beilei Cai, Julien Rombi, Keith L Davis, Nydia Caro, Teddy Saliba
Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future oncology (London, England) (2024)
Ravi K Goyal, Jingchuan Zhang, Keith L Davis, Martina Sluga-O'Callaghan, Peter A Kaufman
Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer. Breast cancer research and treatment 205 (1) (2024)
Muhammad Furqan, Siddharth Karanth, Ravi K Goyal, Beilei Cai, Julien Rombi, Keith L Davis, Nydia Caro, Teddy Saliba
Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future oncology (London, England) (2024)
Freny Vaghaiwalla Mody, Ravi K Goyal, Mayank Ajmera, Keith L Davis, Alpesh N Amin
Exploring the Association Between Heart Rate Control and Rehospitalization: A Real-World Analysis of Patients Hospitalized with Heart Failure with Reduced Ejection Fraction. Drugs - real world outcomes 11 (3) (2024)
Ravi K Goyal, Jingchuan Zhang, Keith L Davis, Martina Sluga-O'Callaghan, Peter A Kaufman
Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer. Breast cancer research and treatment 205 (1) (2024)
Ravi K Goyal, Jingchuan Zhang, Keith L Davis, Martina Sluga-O'Callaghan, Peter A Kaufman
Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer. Breast cancer research and treatment 205 (1) (2024)
Ravi K Goyal, Jingchuan Zhang, Keith L Davis, Martina Sluga-O'Callaghan, Peter A Kaufman
Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer. Breast cancer research and treatment 205 (1) (2024)
Ravi K Goyal, Sean D Candrilli, Susan Abughosh, Hua Chen, Holly M Holmes, Michael L Johnson
Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer. Cancers 16 (12) (2024)
Freny Vaghaiwalla Mody, Ravi K Goyal, Mayank Ajmera, Keith L Davis, Alpesh N Amin
Exploring the Association Between Heart Rate Control and Rehospitalization: A Real-World Analysis of Patients Hospitalized with Heart Failure with Reduced Ejection Fraction. Drugs - real world outcomes (2024)
María Díez-Campelo, Aylin Yucel, Ravi K Goyal, Rohan C Parikh, Elizabeth Esterberg, Maria Jimenez, Martina Sluga-O'Callaghan, Dimana Miteva, Hong Xiao, Ulrich Germing
Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe. Future oncology (London, England) (2024)
Ravi K Goyal, Sean D Candrilli, Susan Abughosh, Hua Chen, Holly M Holmes, Michael L Johnson
Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer. Cancers 16 (12) (2024)
Freny Vaghaiwalla Mody, Ravi K Goyal, Mayank Ajmera, Keith L Davis, Alpesh N Amin
Exploring the Association Between Heart Rate Control and Rehospitalization: A Real-World Analysis of Patients Hospitalized with Heart Failure with Reduced Ejection Fraction. Drugs - real world outcomes 11 (3) (2024)
Ravi K Goyal, Holly M Holmes, Hua Chen, Susan Abughosh, Sean D Candrilli, Michael L Johnson
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast cancer research and treatment 198 (1) (2023)
Ravi K Goyal, Hua Chen, Susan M Abughosh, Holly M Holmes, Sean D Candrilli, Michael L Johnson
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer 129 (7) (2023)
Paul K Paik, Ravi K Goyal, Beilei Cai, Mark A Price, Keith L Davis, Valerie Derrien Ansquer, Nydia Caro, Teddy R Saliba
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future oncology (London, England) (2023)
Ravi K Goyal, Holly M Holmes, Hua Chen, Susan Abughosh, Sean D Candrilli, Michael L Johnson
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast cancer research and treatment 198 (1) (2023)
Ravi K Goyal, Hua Chen, Susan M Abughosh, Holly M Holmes, Sean D Candrilli, Michael L Johnson
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer 129 (7) (2023)
Ravi K Goyal, Holly M Holmes, Hua Chen, Susan Abughosh, Sean D Candrilli, Michael L Johnson
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast cancer research and treatment (2023)
Ravi K Goyal, Holly M Holmes, Hua Chen, Susan Abughosh, Sean D Candrilli, Michael L Johnson
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast cancer research and treatment 198 (1) (2023)
Ravi K Goyal, Jingchuan Zhang, Keith L Davis, Martina Sluga-O'Callaghan, Peter A Kaufman
Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy. Breast cancer (Dove Medical Press) 15 (2023)
Ravi K Goyal, Hua Chen, Susan M Abughosh, Holly M Holmes, Sean D Candrilli, Michael L Johnson
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer (2023)
Ravi K Goyal, Hua Chen, Susan M Abughosh, Holly M Holmes, Sean D Candrilli, Michael L Johnson
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer 129 (7) (2023)
Ravi K Goyal, Hua Chen, Susan M Abughosh, Holly M Holmes, Sean D Candrilli, Michael L Johnson
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer 129 (7) (2023)
Ravi K Goyal, Saurabh P Nagar, Shaum M Kabadi, Hannah Le, Keith L Davis, James A Kaye
Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population. Cancer medicine 10 (8) (2021)
Ravi K Goyal, Preetesh Jain, Saurabh P Nagar, Hannah Le, Shaum M Kabadi, Keith Davis, James A Kaye, Xianglin L Du, Michael L Wang
Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leukemia & lymphoma 62 (6) (2021)
Ravi K Goyal, Gebra Cuyun Carter, Saurabh P Nagar, Emily Nash Smyth, Gregory L Price, Rohan C Parikh, Yu-Jing Huang, Li Li, Keith L Davis, James A Kaye
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert review of pharmacoeconomics & outcomes research 21 (4) (2020)
Shaum M Kabadi, Ravi K Goyal, Saurabh P Nagar, James A Kaye, Keith L Davis
Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer medicine 8 (8) (2019)
Ravi K Goyal, Gebra Cuyun Carter, Saurabh P Nagar, Emily N Smyth, Gregory L Price, Yu-Jing Huang, Li Li, Keith L Davis, James A Kaye
Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer. Current medical research and opinion 35 (10) (2019)